Therapeutic Potential of Berberine
DOI:
https://doi.org/10.62051/4f02q424Keywords:
Berberine, cancer, Type-II diabetes, Gastrointestinal disease, Cholesterol-lowering.Abstract
Berberine, an alkaloid extracted from plants, is used in the treatment of many diseases, has many pharmacological effects, and is accompanied by a high safety profile, which is popular in drug development and has been applied in many diseases. It shows significant effects on cancer, type 2 diabetes mellitus, gastrointestinal diseases, and cholesterol reduction as the inherent properties of berberine have inhibitory effects on these conditions, some by targeting specific steps in the disease progression, and others by acting directly on the pathogens themselves. Additionally, berberine also has several side effects, and patients should be cautious to avoid exceeding the recommended dosage. Also, it may interact with certain medications, presenting both benefits and risks. Therefore, it is important to take berberine under medical supervision and follow the doctor's advice. This article summarizes several clinical trials, randomized controlled trials, and other experimental studies, including in vivo and in vitro experiments. During this review, it will focus on these four kinds of diseases, to explain the mechanism and description of the relationship between disease and berberine.
Downloads
References
[1] K. Wang, .X Feng, L. Chai, F. Qiu, The metabolism of berberine and its contribution to the pharmacological effects, Drug Metabolism Reviews, 49(2017)139-57.
[2] S. Habtemariam, Berberine pharmacology and the gut microbiota: A hidden therapeutic link, Pharmacological Research, 155(2017)104722.
[3] D. Song, I. Hao, D. Fan, Biological properties and clinical applications of berberine, Frontiers of Medicine, 14(2020)564-82.
[4] P.S. Roy, B.J. Saikia, Cancer and cure: A critical analysis, Indian Journal of Cancer, 53(2016)441-2.
[5] L. Guamán Ortiz, P. Lombardi, M. Tillhon, A. Scovassi, Berberine, an Epiphany Against Cancer, Molecules, 19(2014)12349-67.
[6] M. Javed Iqbal, C. Quispe, Z. Javed, H. Sadia, Q.R. Qadri, S. Raza, et al, Nanotechnology-Based Strategies for Berberine Delivery System in Cancer Treatment: Pulling Strings to Keep Berberine in Power, Frontiers in Molecular Biosciences, 15(2021)7.
[7] Y. Wang, A. Yan, S. Li, B. Liu, H. Li, Y. Yan, Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review, Medicine, 98(2019) e16947.
[8] N. Javeed, A.V. Matveyenko, Circadian Etiology of Type 2 Diabetes Mellitus, Physiology, 33(2018)138–50.
[9] Y. Zhang, Y. Gu, H. Ren, S. Wang, H. Zhong, X. Zhao, et al, Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study), Nature Communications, 11(2020)5015.
[10] X. Chen, Y. Chen, H. Bi, X. Zhao, L. Zhang, J. Liu, et al, Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori, Journal of Digestive Diseases, 23(2022)568–76.
[11] D.Y. Graham, A. Shiotani, New concepts of resistance in the treatment of Helicobacter pylori infections, Nature Clinical Practice Gastroenterology & Hepatology, 5(2008)321–31.
[12] T. Yang, R. Wang, H. Liu, L. Wang, J. Li, S. Wu, et al, Berberine regulates macrophage polarization through IL-4-STAT6 signaling pathway in Helicobacter pylori-induced chronic atrophic gastritis, Life Sciences, 266(2021)118903.
[13] Y. Song, J. Liu, K. Zhao, L. Gao, J. Zhao, Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases, Cell Metabolism, 33(2021)1911–25.
[14] W. Kong, J. Wei, P. Abidi, M. Lin, S. Inaba, C. Li, et al, Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins, Nature Medicine, 10(2004)1344–51.
[15] J.V. Zhao, W.F. Yeung, Y.H. Chan, D. Vackova, J.Y.Y. Leung, D.K.M. Ip, et al, Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic R andomized Controlled Trial, Nutrients, 13(2021)2550.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
